Tarceva Clinical Trial Information

• What is a clinical trial for patients with cancer?
• Why are clinical trials important?
• Are there different types of clinical trials?
• What is a randomized trial?
• What is a single-blind trial? A double-blind trial?
• Who can join a clinical trial?
• Should I take part in a clinical trial?
• What type of trial was Tarceva's approval based on?
• How did Tarceva (erlotinib) perform in large clinical studies?

Q. What is a clinical trial for patients with cancer?

A clinical trial is medical research conducted in a clinic to determine if new cancer treatments are effective and safe. A clinical trial involving human subjects is one of the last steps in a long and careful process. Researchers often study their ideas in a laboratory for years before a new treatment is tested in cancer patients.

• Back to top

Q. Why are clinical trials important?

A. Clinical trials are important in helping doctors and researchers learn more about cancer and can lead to more effective treatments and care. If a treatment works well in a clinical trial, it may be approved as a new standard treatment and help many cancer patients.

• Back to top

Q. Are there different types of clinical trials?

A. Clinical trials are done in a series of steps called phases.

Phase I

Phase I trials are early studies intended to find out the amount of the drug that works best and how much can be given safely. A small dose is given and then gradually increased while doctors watch closely for unnecessary side effects.

Phase II

Phase II trials also test the safety of the treatment and seek to determine if the treatment is effective. If the treatment works, doctors will plan a Phase III study. If the treatment does not work, no further trials will be conducted.

Phase III

The goal of Phase III trials is to find out if the new treatment is more or less effective than the standard treatment. Phase III trials involve a larger number of subjects and are the type of trials that cancer patients most often join.

• Back to top

Q. What is a randomized trial?

A. A randomized trial is a study in which patients are put into a treatment group by chance. One group will receive the new treatment being studied and the other will receive the standard treatment.

• Back to top

Q. What is a single-blind trial? A double-blind trial?

A. In a single-blind trial, patients do not know which treatment group they are in. In a double-blind trial, neither the patient nor the doctor knows which treatment group the patient is in. Blinded trials are intended to make sure that the results are not biased by anyone's hopes for a certain treatment.

• Back to top

Q. Who can join a clinical trial?

A. Every clinical trial has a list of features - called "eligibility criteria" - that a patient must meet to be able to join the study. These may include age, gender, or type of cancer. Eligibility criteria help doctors determine which patients may be helped the most if a treatment works.

• Back to top

Q. Should I take part in a clinical trial?

A. Once you have qualified for a trial, only you can decide whether to join the study. Before doing so, you should:

• Learn as much as possible about your disease.
• Ask your doctor what clinical trials are open to you; you can also contact the National Cancer Institute (NCI), National Institutes of Health (NIH) and the American Cancer Society (ACS).
• Discuss your feelings about clinical trials with your doctor, nurse, family members and friends.

• Back to top

Q. What type of trial was Tarceva's approval based on?

A. The effectiveness and safety of Tarceva in combination with gemcitabine as a first-line treatment was tested and proven in a randomized, double blind Phase III trial involving 569 patients. These patients had locally advanced, unresectable or metastatic pancreatic cancer.

• Back to top

Q. How did Tarceva (erlotinib) perform in large clinical studies?

A. Tarceva (erlotinib) has been shown to help some patients live longer. In a large clinical study, 23.8% of patients who were taking Tarceva (100mg) plus gemcitabine were living with their pancreatic cancer one year after they started this treatment, compared with 19.4% of patients receiving gemcitabine alone. Additionally, large clinical studies have also proven that Tarceva can slow or stop the growth of cancer cells in some patients.

To find additional clinical trials for Tarceva, please visit www.clinicaltrials.gov

• Back to top